[{"orgOrder":0,"company":"Lumenis","sponsor":"Bloomage Biotechnology Corp., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Hyaluronate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lumenis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lumenis \/ Lumenis","highestDevelopmentStatusID":"14","companyTruncated":"Lumenis \/ Lumenis"}]

Find Clinical Drug Pipeline Developments & Deals by Lumenis

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : M22 medical wound dressing (sodium hyaluronate) is a versatile laser treatment system based on Lumenis' medical beauty concept of "30% Laser Treatment and 70% Postoperative care.

                          Brand Name : M22 Medical Wound Dressing

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 10, 2023

                          Lead Product(s) : Sodium Hyaluronate

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved

                          Recipient : Bloomage Biotechnology Corp., Ltd

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank